Comprehensive characterization of a Canadian cohort of von Hippel‐Lindau disease patients

Von Hippel‐Lindau disease (VHL) is a heritable condition caused by pathogenic variants in VHL and is characterized by benign and malignant lesions in the central nervous system (CNS) and abdominal viscera. Due to its variable expressivity, existing efforts to collate VHL patient data do not adequately capture all VHL manifestations. We developed a comprehensive and standardized VHL database in the web‐based application, REDCap, that thoroughly captures all VHL manifestation data. As an initial trial, information from 86 VHL patients from the University Health Network/Hospital for Sick Children was populated into the database. Analysis of this cohort showed missense variants occurring with the greatest frequency, with all variants localizing to the α‐ or β‐domains of VHL. The most prevalent manifestations were central nervous system (CNS), renal, and retinal neoplasms, which were associated with frameshift variants and large deletions. We observed greater age‐related penetrance for CNS hemangioblastomas with truncating variants compared to missense, while the reverse was true for pheochromocytomas. We demonstrate the utility of a comprehensive VHL database, which supports the standardized collection of clinical and genetic data specific to this patient population. Importantly, we expect that its web‐based design will facilitate broader international collaboration and lead to a better understanding of VHL.

[1]  Steven J. M. Jones,et al.  CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.

[2]  J. Kuratsu,et al.  Development of Database and Genomic Medicine for von Hippel-Lindau Disease in Japan , 2017, Neurologia medico-chirurgica.

[3]  E. Budtz-Jørgensen,et al.  Prevalence, birth incidence, and penetrance of von Hippel–Lindau disease (vHL) in Denmark , 2016, European Journal of Human Genetics.

[4]  W. Chung,et al.  Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Tan,et al.  Clinical and molecular characteristics of East Asian patients with von Hippel–Lindau syndrome , 2016, Chinese journal of cancer.

[6]  Silvio C. E. Tosatto,et al.  VHLdb: A database of von Hippel-Lindau protein interactors and mutations , 2016, Scientific Reports.

[7]  L. Sunde,et al.  Identification of 3 novel VHL germ-line mutations in Danish VHL patients , 2012, BMC Medical Genetics.

[8]  S. Huson,et al.  Birth incidence and prevalence of tumor‐prone syndromes: Estimates from a UK family genetic register service , 2010, American journal of medical genetics. Part A.

[9]  E. Budtz-Jørgensen,et al.  Surveillance in von Hippel‐Lindau disease (vHL) , 2010, Clinical genetics.

[10]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[11]  R. R. Lonser,et al.  von Hippel-Lindau disease , 2003, The Lancet.

[12]  C. A. Friedrich Genotype-phenotype correlation in von Hippel-Lindau syndrome. , 2001, Human molecular genetics.

[13]  Ashutosh Kumar Singh,et al.  Solitary retinal capillary hemangioma: hereditary (von Hippel-Lindau disease) or nonhereditary? , 2001, Archives of ophthalmology.

[14]  D. Long,et al.  Hemangioblastomas of the Central Nervous System in von Hippel-Lindau Syndrome and Sporadic Disease , 2001, Neurosurgery.

[15]  G. Mortier,et al.  Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene , 2000, Human Genetics.

[16]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[17]  W. Kaelin,et al.  The VHL tumour-suppressor gene paradigm. , 1998, Trends in genetics : TIG.

[18]  R. Burk,et al.  A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  F. Chen,et al.  Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A. , 1996, Journal of medical genetics.

[20]  H. Höfler,et al.  Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe , 1996, Human Genetics.

[21]  A. Webster,et al.  Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. , 1996, Journal of medical genetics.

[22]  R. Whitehouse,et al.  A genetic register for von Hippel-Lindau disease. , 1996, Journal of medical genetics.

[23]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[24]  N. Morton,et al.  Von Hippel-Lindau disease: a genetic study. , 1991, Journal of medical genetics.

[25]  M. Ferguson-Smith,et al.  Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.

[26]  M. Kosteljanetz,et al.  Von Hippel-Lindau disease (vHL) , 2013 .

[27]  W. Linehan,et al.  Germline mutations in the Von Hippel‐Lindau disease (VHL) gene in families from North America, Europe, and Japan , 1996, Human mutation.